New drug cocktail shows promise for tough esophageal cancer
NCT ID NCT07455019
First seen Mar 11, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study is testing whether a combination of three treatments—an immunotherapy drug (bemosubaiabimab), a targeted therapy (anlotinib), and standard chemoradiation—can shrink tumors in people with esophageal cancer that has spread to a limited number of other sites (oligometastatic). About 28 adults will receive 4 to 6 cycles of the combination, followed by maintenance therapy with the two drugs. The main goal is to see how many patients have a significant tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Provincial People's Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.